STAT News

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

By STAT News

1 min read
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights